All In Biotech

Drug Trial Radar · NCT04657822

Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

An Open-label, Multi-center, Phase IV, Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

130

Planned (sponsor's estimate)

Start

Jun 10, 2021

Primary completion

Jun 10, 2031

Study completion Jun 10, 2031

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Dec 8, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center multi-national rollover study to allow continued access to crizanlizumab for patients with sickle cell disease (SCD) who are on crizanlizumab treatment in a Novartis-sponsored study (parent study) and are benefiting from the treatment as judged by the investigator.

Conditions

  • Sickle Cell Disease

Interventions

  • CrizanlizumabDrug

    Concentrate for solution for infusion for Intravenous use

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Not Applicable as this protocol is to provide an option for continued access to crizanlizumab for patients with Sickle Cell Disease who have completed a prior Novartis-sponsored Crizanlizumab studyTime frame: Not Applicable - Study Completion

Locations

31 sites in 11 countries. Site status is shown where the registry gives one.

  • University Of Alabama

    Birmingham, Alabama · Recruiting

  • Childrens National Hospital

    Washington D.C., District of Columbia · Active not recruiting

  • Augusta University Georgia

    Augusta, Georgia · Recruiting

  • East Carolina University

    Greenville, North Carolina · Completed

  • East Carolina University

    Greenville, North Carolina · Completed

  • Childrens Hospital of Philadelphia

    Philadelphia, Pennsylvania · Active not recruiting

  • Cook Childrens Medical Center

    Fort Worth, Texas · Completed

  • Novartis Investigative Site

    Brussels, Belgium · Completed

  • Novartis Investigative Site

    Laken, Belgium · Active not recruiting

  • Novartis Investigative Site

    Liège, Belgium · Active not recruiting

  • Novartis Investigative Site

    Salvador, Estado de Bahia, Brazil · Active not recruiting

  • Novartis Investigative Site

    Ribeirão Preto, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    São Paulo, São Paulo, Brazil · Active not recruiting

  • Novartis Investigative Site

    Montería, Colombia · Active not recruiting

  • Novartis Investigative Site

    Barranquilla, Atlántico, Colombia · Recruiting

  • Novartis Investigative Site

    Valledupar, Cesar Department, Colombia · Recruiting

  • Novartis Investigative Site

    Cali, Valle del Cauca Department, Colombia · Active not recruiting

  • Novartis Investigative Site

    Créteil, France · Completed

  • Novartis Investigative Site

    Paris, France · Active not recruiting

  • Novartis Investigative Site

    Paris, France · Completed

  • Novartis Investigative Site

    Heidelberg, Germany · Active not recruiting

  • Novartis Investigative Site

    Padova, PD, Italy · Active not recruiting

  • Novartis Investigative Site

    Orbassano, TO, Italy · Completed

  • Novartis Investigative Site

    Beirut, Lebanon · Recruiting

  • Novartis Investigative Site

    Tripoli, Lebanon · Recruiting

  • Novartis Investigative Site

    Khoudh, Oman · Recruiting

  • Novartis Investigative Site

    Barcelona, Spain · Completed

  • Novartis Investigative Site

    Madrid, Spain · Active not recruiting

  • Novartis Investigative Site

    Hatay, Antakya, Turkey (Türkiye) · Withdrawn

  • Novartis Investigative Site

    Adana, Saricam, Turkey (Türkiye) · Active not recruiting

  • Novartis Investigative Site

    Adana, Yuregir, Turkey (Türkiye) · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.